摘要
目的评价盐酸齐拉西酮(力复君安)治疗首发精神分裂症的疗效及安全性。方法将52例首发精神分裂症患者随机分为齐拉西酮组(27例)和利培酮组(25例),进行为期6周的双盲对照研究。采用阳性和阴性症状量表(PANSS)、临床总体印象量表(CGI)、不良反应量表(TESS)及有关实验室检查评价疗效和安全性。结果治疗结束时,两组PANSS评分较入组时均显著减低(P<0.01);PANSS减分率:齐拉西酮组为(70.10±23.19)%,利培酮组为(71.46±30.55)%;临床总有效率:齐拉西酮组为85.19%,利培酮组为84.00%;两组疗效差异无统计学意义。不良反应的发生率齐拉西酮组为48.28%,利培酮组为57.14%,利培酮组发生例次比齐拉西酮组要多,两组间比较差异无统计学意义。结论国产齐拉西酮治疗首发精神分裂症的疗效和不良反应与利培酮相似,是一种有效、安全的抗精神病药物。
Objective To evaluate the effect and safety of ziprasidone in the treatment of first-episode schizophrenia. Methods 52 patients with first-episode schizophrenia were randomly divided into two groups（A＆B） to conduct a 6-week double-blind contrast study, among which 27 patients in group A were treated with ziprasidone, and the other 25 in group B were treated with risperidone.PANSS, CGI, TESS and related laboratory test were adopted to evaluate the effect and safety. Results After the treatment, PANSS scores of the two groups dropped dramatically from the very beginning （P〈0.01）, with a rate of （70.10±23.19）% in group A and （71,46±30.55）% in group B. The clinical total effective rate was 85.19% with group A and 84.00% with group B. Rate of side effects was 57.14% in group B, higher than that in group A which was 48.28%. No statistical differences were found between the two groups. Conclusion The effect of domestic ziprasidone in the treatment of first-episode schizophrenia is similar with that of risperidone. Ziprasidone is an effective and safe antipsychotics.
出处
《中国现代医药杂志》
2008年第6期61-64,共4页
Modern Medicine Journal of China
